Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean dextrose and fructose and phosphoric acid?
Displaying drugs 2126 - 2150 of 15113 in total

Insulin glargine

Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the...
Approved
Matched Description: … and proteolysis. ... tissues such as the liver, fat cells, and skeletal muscle. ... addition of two arginines to the C-terminus (positions B31 and 32) of the B-chain. …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... insulin glargine and lixisenatide ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Dronedarone

Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate control, rhythm control, prevention...
Approved
Matched Description: … toxicities, such as thyroid and pulmonary toxicities. ... calcium ion channels and inhibiting β-adrenergic receptors. ... It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of …

Mebrofenin

Approved
Experimental
Matched Iupac: … 2-({[(3-bromo-2,4,6-trimethylphenyl)carbamoyl]methyl}(carboxymethyl)amino)acetic acid …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Donislecel

Donislecel is the first allogeneic pancreatic islet cellular from deceased donor pancreatic cells used for the treatment of adult type 1 diabetes with unsuccessful control of glycated hemoglobin, despite intensive diabetes management and treatments.[L47166,L47196] The primary mechanism of action of donislecel is attributed to the secretion of insulin and other...
Approved
Matched Description: … 1 diabetes with unsuccessful control of glycated hemoglobin, despite intensive diabetes management and ... other pancreatic hormones from infused allogeneic islet cells to mimic endogenous glucose control and ... L47166,L47196] The primary mechanism of action of donislecel is attributed to the secretion of insulin and …
Matched Categories: … Cellular and Gene Therapy …

Cefadroxil

Long-acting, broad-spectrum, water-soluble, cephalexin derivative.
Approved
Vet approved
Withdrawn
Matched Iupac: … amino-2-(4-hydroxyphenyl)acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid …

Cefprozil

Cefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others.
Approved
Matched Iupac: … -hydroxyphenyl)acetamido]-8-oxo-3-(prop-1-en-1-yl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid …
Matched Description: … skin, bronchitis, and others. ... antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and …

Nelfinavir

Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Approved
Matched Description: … It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children …

Isavuconazonium

Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it...
Approved
Investigational
Matched Description: … [A38834] It is the prodrug form of isavuconazole, the active moiety, and it is available in oral and ... Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July ... 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed …
Matched Categories: … Isavuconazole and Prodrugs …

Avibactam

Avibactam is a non-β-lactam β-lactamase inhibitor that is available in combination with ceftazidime (Avycaz). This combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal infections in combination with metronidazole, and the treatment of complicated urinary tract infections, including pyelonephritis caused by antibiotic resistant-pathogens,...
Approved
Matched Iupac: … [(2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl]oxidanesulfonic acid …
Matched Description: … 2015 for the treatment of complicated intra-abdominal infections in combination with metronidazole, and ... As there is limited clinical safety and efficacy data, Avycaz should be reserved for patients over 18 …

Propyliodone

Radiopaque medium usually in oil; used in bronchography.
Approved

Ramucirumab

Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability,...
Approved
Investigational
Matched Description: … , and migration of human endothelial cells. ... By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby ... VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Buserelin

Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). It is used in prostate cancer treatment.
Approved
Investigational
Matched Categories: … Hormones and Related Agents ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …

1,2-Distearoyllecithin

Approved
Experimental

Artemotil

Artemotil, also known as β-arteether, is a semi-synthetic derivative of artemisinin and a fast acting blood schizonticide specifically indicated for the treatment of chloroquine-resistant Plasmodium falciparum malaria and cerebral malaria cases.
Approved
Matched Description: … Artemotil, also known as β-arteether, is a semi-synthetic derivative of artemisinin and a fast acting ... schizonticide specifically indicated for the treatment of chloroquine-resistant _Plasmodium falciparum_ malaria and …
Matched Categories: … Artemisinin and derivatives ... Antiparasitic Products, Insecticides and Repellents …

Tebentafusp

Tebentafusp is a gp100 peptide-HLA-directed CD3 T cell engager. It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs), a recently developed cancer immunotherapy with a novel mechanism of action. ImmTACs bind to target cancer cells that express a specific antigen of...
Approved
Investigational
Matched Description: … [L39995] It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T ... ImmTACs bind to target cancer cells that express a specific antigen of interest and recruit cytotoxic ... being the first and only therapy for the treatment of unresectable or metastatic uveal melanoma to be …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Ceftolozane

Ceftolozane is a semi-synthetic broad-spectrum fifth generation cephalosporin. It was approved by the FDA in 2014 for use in combination with Tazobactam for the treatment of serious infections, such as intra-abdominal infections and complicated urinary tract infections. The manufacturer of this drug is Cubist Pharmaceuticals. Most recently, in June 2019,...
Approved
Investigational
Matched Description: … and mortality in hospitalized patients and the use of ceftolozane-tazobactam offers effective activity ... 2019, ceftolozane-tazobactam was approved for the treatment of hospital-acquired bacterial pneumonia and ... combination with [Tazobactam] for the treatment of serious infections, such as intra-abdominal infections and …

Ferrous bisglycinate

Ferrous bisglycinate is a chelate that is used as a source of dietary iron. Forming a ring structure when reacting with glycine, ferrous bisglycinate acts as both a chelate and a nutritionally functional . It is found in foods for food enrichment or in supplements for the treatment of iron...
Approved
Matched Description: … Forming a ring structure when reacting with glycine, ferrous bisglycinate acts as both a chelate and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Toripalimab

The proliferation of some cancers can be attributed, at least in part, to the suppression of host tumor surveillance. One mechanism by which this occurs is through the overexpression of programmed cell death ligand (PD-L1) - the binding of PD-L1 (and PD-L2) to its target receptor (PD-1) results in the...
Approved
Investigational
Matched Description: … production, and thus its overexpression can inhibit T-cell-mediated immune surveillance of tumors. ... through the overexpression of programmed cell death ligand (PD-L1)[A261506] - the binding of PD-L1 (and ... PD-L2) to its target receptor (PD-1) results in the inhibition of T-cell proliferation and cytokine …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Onasemnogene abeparvovec

Onasemnogene abeparvovec is an adeno-associated virus vector-based gene therapy that has been approved by the FDA in May 2019 for the treatment of infant patients (less than 2 years of age) with spinal muscular atrophy (SMA) and a specific mutation in the survival motor neuron 1 (SMN1) gene. SMA is...
Approved
Matched Description: … to debilitating and often fatal muscle weakness. ... for the treatment of infant patients (less than 2 years of age) with spinal muscular atrophy (SMA) and ... complete paralysis of the limbs and permanent dependence on ventilators, has not been evaluated. …
Matched Categories: … Cellular and Gene Therapy ... Amino Acids, Peptides, and Proteins …

Empagliflozin

Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor...
Approved
Matched Description: … led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014 ... the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart ... [A203453] It is used clinically as an adjunct to diet and exercise, often in combination with other drug …
Matched Categories: … Alimentary Tract and Metabolism ... metformin and empagliflozin ... linagliptin and empagliflozin ... metformin, linagliptin and empagliflozin …

Avacopan

Anti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis (AAV) is a rare (estimated incidence of 3 cases per 100,000 per year) form of "pauci-immune" systemic small-vessel vasculitis typified by the presence of ANCAs in the serum.[A240249, A240254, A227003] The full spectrum of AAV includes granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis...
Approved
Investigational
Matched Description: … AAV may be associated with necrotizing and crescentic glomerulonephritis (NCGN). ... , in particular, the interaction between the anaphylatoxin fragment C5a and its cognate C5aR receptor ... [A240269, A240329, L38919] Avacopan was granted FDA approval on October 8, 2021, and is currently …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Alteplase

Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin.[A252330,L43125] Alteplase...
Approved
Investigational
Matched Description: … alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and ... thrombolytic agents derived from tissue plasminogen activator, such as [desmoteplase], [tenecteplase] and ... alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and …
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Ofatumumab

Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is...
Approved
Matched Description: … In February 2020, FDA and EMA approved Supplemental Biologics License Application (sBLA) and Marketing ... [A6921] Ofatumumab is available for intravenous administration and is marketed as Arzerra. ... IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Eflapegrastim

Febrile neutropenia (FN), defined as the co-occurrence of fever (temperature > 38 ◦C) and severe neutropenia (ANC < 500 cells/mm3), is a potential side effect of myelosuppressive chemotherapy in which the patient develops an infection during a period of significant neutropenia. It typically develops during the first cycle of chemotherapy...
Approved
Investigational
Matched Description: … risk of morbidity and mortality. ... Febrile neutropenia (FN), defined as the co-occurrence of fever (temperature > 38 ◦C) and severe neutropenia ... [A252320] It typically develops during the first cycle of chemotherapy and is associated with an increased …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …

Palifermin

Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.
Approved
Matched Description: … It is 140 residues long, and is produced using E. coli. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …
Displaying drugs 2126 - 2150 of 15113 in total